Acceleron Pharma Inc (XLRN)

34.83
NASDAQ : Health Care
Prev Close 35.05
Day Low/High 34.36 / 35.46
52 Wk Low/High 23.07 / 41.69
Avg Volume 387.20K
Exchange NASDAQ
Shares Outstanding 38.69M
Market Cap 1.36B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acceleron Showcases Vision And Strategy At 2017 R&D Day

Acceleron Showcases Vision And Strategy At 2017 R&D Day

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, hosted its Research and Development (R&D) Day in New...

Acceleron To Develop Sotatercept In Pulmonary Arterial Hypertension

Acceleron To Develop Sotatercept In Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept...

Acceleron To Host Research And Development Day On September 19, 2017

Acceleron To Host Research And Development Day On September 19, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will webcast a live presentation from its Research and Development (R&D) Day on Tuesday, September 19, 2017.

Acceleron Announces Publication Of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results In The Lancet Oncology

Acceleron Announces Publication Of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results In The Lancet Oncology

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, announced that The...

XLRN Crosses Above Average Analyst Target

In recent trading, shares of Acceleron Pharma, Inc. have crossed above the average analyst 12-month target price of $37.40, changing hands for $38.76/share.

Acceleron Pharma Reports Second Quarter 2017 Operational And Financial Results

Acceleron Pharma Reports Second Quarter 2017 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

Acceleron Announces First Patient Treated In Phase 2 Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Announces First Patient Treated In Phase 2 Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron To Webcast Second Quarter 2017 Financial Results On August 3, 2017

Acceleron To Webcast Second Quarter 2017 Financial Results On August 3, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 3, 2017 at 5:00 p.

Acceleron Provides Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia At The 22nd Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Acceleron Provides Updated Results From Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 22nd Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Biotech Movers: Acceleron, Clovis, Coherus

Biotech Movers: Acceleron, Clovis, Coherus

Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday.

Acceleron Announces Top-Line Results From DART Phase 2 Study Of Dalantercept In Advanced Renal Cell Carcinoma

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Celgene And Acceleron Complete Target Enrollment In The MEDALIST And BELIEVE Phase 3 Studies Of Luspatercept In Myelodysplastic Syndromes And Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIST and BELIEVE Phase 3 studies of luspatercept in patients with...

Acceleron To Participate In Two Healthcare Investor Conferences In June

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Clinical Presentations On Luspatercept At The 22nd Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Reports First Quarter 2017 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

Luspatercept Phase 2 Data Presented At The 14th International Symposium On Myelodysplastic Syndromes

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Acceleron Announces Management Change

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics As Head Of Biologics

Dr. Grinberg, senior scientist with 12 years of biotech industry experience in biologics discovery and development, joins Dragonfly's team to accelerate development of its novel Natural Killer cell-based immunotherapies.

Acceleron To Participate In Two Healthcare Investor Conferences In May

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Acceleron Provides Clinical Development Updates On Luspatercept Program

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Acceleron To Host Webcast To Review First Quarter 2017 Financial And Operational Results On May 8, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Clinical Presentations On Luspatercept At The 14th International Symposium On Myelodysplastic Syndromes

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Plans To Initiate A Phase 2 Trial Of ACE-083 In Charcot-Marie-Tooth Neuromuscular Disease And Host Educational Webinar

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Price Target Raised by Leerink

Acceleron Pharma Price Target Raised by Leerink

The company reported a fourth quarter loss on Wednesday.

Acceleron Reports Fourth Quarter And Year Ended 2016 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

Acceleron To Participate In Two Healthcare Investor Conferences In March

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

TheStreet Quant Rating: D (Sell)